Resilient Biotics develops microbiome-based therapeutics using big data analytics and proprietary genomic databases to create precision microbial treatments for respiratory infectious diseases. Their approach aims to reduce reliance on antibiotics by utilizing healthy microorganisms to prevent pathogen colonization.
Funding
$11.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
BCFGFounders
Product
Problem
Respiratory infectious diseases pose a significant threat to both human and animal health, often requiring antibiotic treatments that can lead to resistance and disrupt the natural microbiome. Current treatment strategies may not always be effective and can have unintended consequences on the host's microbial ecosystem.
Solution
Resilient Biotics is developing microbiome-based therapeutics designed to prevent respiratory infections and reduce the reliance on antibiotics. The company leverages advanced microbiome genomics and data science to identify and develop precision microbial treatments. By harnessing the power of commensal microorganisms, Resilient Biotics aims to create a protective barrier against dangerous pathogens, offering a more effective and sustainable approach to managing respiratory health. Their proprietary databases and analytics pipelines serve as a discovery engine for novel microbiome products.
Target Audience
The primary target audience includes individuals and animals susceptible to respiratory infectious diseases, as well as healthcare providers and veterinarians seeking alternative treatment options to antibiotics.
Features
- Proprietary genomic databases for identifying beneficial microorganisms.
- Advanced analytics pipelines for therapeutic discovery.
- Focus on non-antibiotic, precision microbial therapeutics.
- Applications in both animal and human health.
- Development of treatments designed from the commensal microbial community.